Clinical Trial Update: Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating docetaxel versus oxaliplatin added to S-1 for stage II/III gastric adenocarcinoma; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Gastric Cancer | Phase 3 | Status: UNKNOWN